ARTICLE | Clinical News
Vivelle-Dot transdermal 17-beta estradiol regulatory update
December 17, 2001 8:00 AM UTC
The partners received an approvable letter from the FDA to expand the use of Vivelle-Dot to prevent postmenopausal osteoporosis. The product is marketed to treat the condition. ...